Follow-On Biologics Would Save $71 Billion Over 10 Years, Express Scripts Estimates
The PBM report models savings stemming from the use of biosimilars for interferons, erythropoietin, growth hormone and insulin.
The PBM report models savings stemming from the use of biosimilars for interferons, erythropoietin, growth hormone and insulin.